top of page

Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry

Our team

Board of Directors

Raphaël Wisniewski

Chairman of the Board

Raphael joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2001. Previously, he worked in Healthcare Corporate Finance at Goldman Sachs, starting at Salomon Smith Barney. He is a graduate of the Ecole des Hautes Etudes Commerciales and holds a postgraduate diploma in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris. Raphaël is a Director of Axonics, Poxel, ReViral, MedDay, Grey Wolf, Enyo Pharma and Dynacure. 

Sofia Ioannidou, PhD

Board Member

Sofia joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2009. Prior to this, she worked as a consultant at LEK Consulting in London and as a research scientist at Eyetech Pharmaceuticals in Boston, USA. Sofia obtained her first degree in Molecular and Cellular Biochemistry from the University of Oxford and her PhD in Cell Biology from Cancer Research UK. Sofia is a board member of LogicBio Therapeutics, Tricares, Avalyn Pharma and Sanifit. 

Frank Mühlenbeck, PhD

Board Member

Frank is a Senior Investment Manager at LBBW Venture Capital GmbH where he manages life science investments. Prior to this, he was managing director at EMBL Ventures, a venture capital firm associated with the European Molecular Biology Laboratory ( Before that, Frank was founding partner of a large family office in Switzerland where he was responsible for public and private life science investments in Europe and the US. His transaction experience covers M&A’s as well as IPO’s (Euronext, NASDAQ). Frank started his career after his PhD in basic tumor research at Steinbeis, a German technology transfer organization with headquarters in Stuttgart.. 

Vikram Sudarsan, PhD

Board Member

Vikram received his PhD in Neuroscience from the University of Sheffield, UK and thereafter held a post-doctoral research position at Stanford School of Medicine. Vikram is an investor and entrepreneur with over 25 years of experience in the pharma industry. His experience spans a wide spectrum of industry functions including venture capital, business development, transactions, market access and drug development. Vikram was CEO of Cipla and built a pipeline of branded products to treat disorders of the CNS. He served on the boards of Stempeutics, Chase Pharmaceuticals and Cipla. 

bottom of page